Drug sensitivity analysis revealed that patients with high-risk prostate cancer BCR may be more sensitive to the PARP inhibitor olaparib, which has been demonstrated in clinical trials, and that the drug is particularly effective in BRCA-positive metastatic prostate cancer [62,63]. The gene discussed is BCR; the disease is Familial prostate cancer.